All lobbying filings

BROWNSTEIN HYATT FARBER SCHRECK, LLP

BROWNSTEIN HYATT FARBER SCHRECK, LLP filed a Q2 report for FERRING PHARMACEUTICALS INC. on July 20, 2026, reporting $50,000 in lobbying income.

Lobbying for FERRING PHARMACEUTICALS INC. · biopharmaceutical company

All filings by BROWNSTEIN HYATT FARBER SCHRECK, LLP · Everything FERRING PHARMACEUTICALS INC. has reported

Filing · LD-2 quarterly report Q2 report

Reporting period

2nd Quarter 2026

Apr 1 - June 30 · Posted Jul 20, 2026

Income

$50,000

What the client paid this registrant for the period.

Client based in

New Jersey

Official filing document

Lobbyists on this filing 1

RUSSELL W. SULLIVAN New on this filing

Previously held: Staff Director, Senate Finance Committee; Chief Counsel, Senate Finance Committee; Leg. Director, Sen. Bob Graham

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 4

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 3

Trade (domestic/foreign)

Issues related to pharmaceutical tariffs

Health Issues

Issues related to microbiome, oncology, & fertility Issues related to formulary tier status Drug pricing policy Healthcare policy in the NDAA IVF Tax credit FDA Review programs

Veterans

Issues related to veteran's care and veteran's reproductive care

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.